Yissum Technology Transfer Company of the Hebrew University of Jerusalem has signed a new licensing agreement with a Belgian holding company for the commercialization of a new clean technology developed at the university.

Yissum Technology Transfer Company of the Hebrew University of Jerusalem has signed a new licensing agreement with a Belgian holding company for the commercialization of a new clean technology developed at the university.

Hebrew University Prof. Joseph Almog developed a kit for the detection of Urea Nitrate  (Hebrew Article)

Prof. Nathan Citri of the Hebrew University of Jerusalem invented a kit for the rapid detection of anthrax.

The research, patented by Yissum,  could lead to a new class of antibiotics

The company first plans to raise several million dollars in a private placement.

Investment bank Goldman Sachs is investing $100 million in the Israeli company Mobileye. This reflects a valuation of $600 million. 

Hebrew University and the technology transfer company Yissum announced on Wednesday that formation of a new consortium to develop water technology, the first such project in Israel.

The consortium has been awarded an operational budget for three years by the chief scientist's office in the Industry, Trade and Labor Ministry, with funding for the first year standing at NIS 15 million. 

According to consortium representatives, the group hopes to find effective solutions to battle biofouling and also to develop new and useful methods to treat and save water.

The treatment was found in testing to have eliminated four different types of allergic diseases in mice.

Protalix BioTherapeutics, Inc. , today announced it has signed an agreement with the Yissum Research and Development Company, the technology transfer arm of the Hebrew University of Jerusalem, Israel, and the Boyce Thompson Institute for Plant Research, at Cornell University, Ithaca, New York, to develop a proprietary plant cell-based acetylcholinestrase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, including a biodefense program.

Neocrine Biosciences Inc. will develop valnoctamide, which has potential for treating neurological and psychiatric disorders discovered at Hebrew University.

Prof. Naftali Tishby dreams of the day when we will be able transfer a copy of our souls onto the computer before our death so that the soul will continue to think, feel, and answer our grandchildren's questions long after our bodies disintegrate. Prof. Tishby of the Interdisciplinary Center for Neural Computation (ICNC) at the Hebrew University of Jerusalem believes that this day is near. 

The French-Israeli eye drug maker uses technology developed by the Hebrew University of Jerusalem.

Merck shopping for new technologies for the improvement of drug development 

Jerusalem Development Authority allocates initial 10 million NIS to BioJerusalem

Reinventing the wheel- the latest car technology on the Wall Street Journal

A Hebrew University doctoral student who is the first cousin of the president of Chile has won a prestigious research prize for developing a "knockout technique" in special "antibody nose drops" against allergies that he tested successfully on lab mice. 

Nava Swersky Sofer isn't the type of person to look back at her accomplishments and congratulate herself. Instead, she says, she's a forward thinker who focuses keenly on her next move.